Solid first quarter leaves J&J investors nonplussed

16 April 2024
j-j_johnson_lobby_large

US healthcare giant Johnson & Johnson (NYSE: JNJ) has announced its financial results for the first quarter of 2024.

The conglomerate posted $21.38 billion in total sales, up more than 2% from the same quarter in 2023 and marginally below the $21.4 billion expected by Wall Street analysts, based on a survey of analysts by LSEG.

"Reflects our sharpened focus and the progress in our portfolio and pipeline"Excluding certain items, adjusted earnings per share were $2.71, a 12% rise on a year ago and ahead of the $2.64 anticipated by analysts.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical